ResMed Inc. RMD SPX

Q: What is the current share price of ResMed Inc. (RMD)?

As of 2026-07-14 21:23 PDT, ResMed Inc. (RMD) trades at $193.01 on NYSE. Its 52-week range is $182.82 to $291.49.

Q: What is the market capitalisation of RMD?

ResMed Inc. (RMD) has a market capitalisation of $28.00B on NYSE.

Q: What is the P/E ratio of RMD?

RMD trades at a trailing price-to-earnings (P/E) ratio of 18.63. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.35.

Q: Does RMD pay a dividend?

ResMed Inc. (RMD) currently offers a dividend yield of 1.23%.

Q: What is the return on equity (ROE) of RMD?

RMD has a return on equity (ROE) of 25.25%. Its return on capital employed (ROCE) is 23.55%.

Q: Is RMD a good stock to buy?

This page provides a data-driven analysis of ResMed Inc. (RMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Instruments & Supplies · United States

https://www.resmed.com

Company Profile ↓

$193.01

-23.30% 1Y

Mkt Cap$28.00B

P/E18.63

P/B4.35

Div. Yield1.23%

52W High$291.49

52W Low$182.82

Book Value$44.76

EPS (TTM)$10.36

Company Overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 25.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 23.5%.

Consistent Profit Growth

Net profit has compounded at 15.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.4% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 18.6, below the sector median of 25.4.

Healthy Margins

Maintains a net profit margin of 27.4%.

Recent Developments

Jun 2025 Revenue of $5.15B (+9.8% YoY); net profit $1.40B.
Trailing 12 Months Year-on-year growth — revenue +10.8%, earnings +10.5%.
5-Year Trend Long-term compounding — revenue CAGR 11.4%, profit CAGR 15.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	11.36%
1 Year:	10.80%

Compounded Profit Growth

5 Years:	15.16%
1 Year:	10.50%

Stock Price Performance

1 Year:	-23.30%
6 Months:	-23.15%
3 Months:	-15.93%
1 Month:	+0.32%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 9% of range

$182.82 $291.49

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)43.08 · Neutral

Price Performance

1M+0.32%

3M-15.93%

6M-23.15%

1Y-23.30%

Valuation vs Sector

P/E of 18.63 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 25.2%.
Healthy ROCE of 23.5%.
Excellent profit margin of 27.4%.
Compounding revenue at 11.4% over 5 years.
Profit CAGR of 15.2% over 5 years.
Generates positive free cash flow.

CONS

Trading 33.8% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

18.63

Industry PE

25.41

Forward P/E

15.90

PEG Ratio

1.15

Book Value

$44.76

Price to Book

4.35

P/S

5.10

EV/EBITDA

12.95

Dividend Yield

1.23%

Growth (CAGR)

Revenue 5Y

11.36%

Profit 5Y

15.16%

Revenue (YoY)

10.80%

Earnings (YoY)

10.50%

Profitability & Returns

ROCE

23.55%

ROE

25.25%

ROA

14.71%

Profit Margin

27.44%

Op Margin

35.33%

Gross Margin

62.18%

EPS (Latest Qtr)

$2.74

EPS (TTM)

$10.36

Balance Sheet & Liquidity

Debt/Equity

0.13

Quick Ratio

2.00

Current Ratio

3.01

Debt

$843.17M

Total Assets

$8.78B

Current Assets

$3.51B

Working Capital

$2.49B

Ownership

Promoter Holding

0.50%

Chg in Prom Hold

FII / Inst Holding

70.03%

Chg in FII Hold

0.03%

Financial Snapshot

Enterprise Value

$28.00B

Total Revenue (TTM)

$5.54B

EBITDA

$2.12B

Free Cash Flow

$1.45B

Operating Cash Flow

$1.89B

Shares Outstanding

145.06M

Gross Margin

62.18%

Payout Ratio

22.47%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	RMD ResMed Inc. SPX	193.01	18.63	$28.00B	1.23%	23.55%	25.25%	11.36%	15.16%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2013	Dec 2013	Mar 2014	Sep 2014	Dec 2014	Mar 2015	Sep 2015	Dec 2015	Mar 2016	Sep 2016	Dec 2016	Mar 2017	Sep 2017	Dec 2017	Mar 2018	Sep 2018	Dec 2018	Mar 2019	Sep 2019	Dec 2019	Mar 2020	Sep 2020	Dec 2020	Mar 2021	Sep 2021	Dec 2021	Mar 2022	Sep 2022	Dec 2022	Mar 2023	Sep 2023	Dec 2023	Mar 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	681.06M	736.16M	769.46M	751.94M	800.01M	768.77M	904.01M	894.87M	864.50M	950.29M	1.03B	1.12B	1.10B	1.16B	1.20B	-	-	1.29B	1.35B	1.34B	1.42B	1.43B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	525.33M	527.92M	514.76M	544.08M	540.43M
Gross Profit	227.98M	248.76M	251.79M	237.31M	263.22M	251.43M	238.62M	266.51M	259.88M	269.18M	309.07M	299.71M	305.61M	349.79M	344.30M	343.09M	374.53M	380.97M	391.62M	427.13M	449.66M	438.66M	462.48M	447.26M	506.29M	504.32M	491.20M	540.81M	579.72M	617.75M	600.06M	646.93M	692.78M	-	-	766.41M	820.07M	820.82M	878.72M	890.98M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	340.14M	363.50M	358.47M	381.13M	391.17M
Operating Income	96.88M	105.02M	104.70M	94.67M	109.15M	105.87M	98.03M	107.98M	104.31M	94.15M	96.89M	107.40M	112.56M	146.02M	136.37M	144.13M	157.08M	156.98M	171.10M	197.81M	217.50M	216.90M	221.72M	223.43M	261.91M	248.71M	234.26M	275.74M	280.19M	300.67M	289.00M	275.09M	374.58M	-	-	426.27M	456.57M	462.35M	497.60M	499.81M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	478.18M	530.86M	520.02M	559.92M	568.84M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	417.69M	458.05M	446.79M	496.15M	502.31M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	52.65M	78.35M	98.26M	103.56M	103.58M
Net Income	80.93M	86.64M	89.97M	83.26M	91.18M	90.98M	82.92M	95.58M	90.79M	76.11M	76.74M	87.82M	86.12M	9.53M	110.12M	105.74M	124.64M	105.42M	120.15M	160.55M	163.14M	178.37M	179.51M	-78.48M	203.61M	201.75M	179.01M	210.48M	224.91M	232.50M	219.42M	208.80M	300.49M	-	-	365.04M	379.70M	348.54M	392.59M	398.73M
Diluted EPS	0.56	0.60	0.63	0.58	0.64	0.64	0.58	0.68	0.64	0.54	0.54	0.62	0.60	0.07	0.76	0.73	0.86	0.73	0.83	1.10	1.12	1.22	1.23	-0.54	1.39	1.37	1.22	1.43	1.53	1.58	1.49	1.42	2.04	-	-	2.48	2.58	2.37	2.68	2.74
R&D Expense	27.36M	29.54M	29.53M	30.02M	29.29M	27.02M	27.19M	28.97M	28.11M	34.45M	38.19M	35.13M	37.41M	40.64M	37.43M	38.79M	43.11M	47.61M	48.03M	49.94M	51.45M	54.53M	54.94M	55.94M	59.95M	62.51M	66.80M	63.19M	69.87M	76.44M	75.71M	73.88M	77.07M	79.52M	81.37M	83.94M	-	87.32M	90.97M	94.27M

Profit & Loss (Annual)

Figures in USD.

Metric	Jun 2009	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Revenue	920.74M	1.09B	1.24B	1.37B	1.51B	1.55B	1.68B	1.84B	2.07B	2.34B	2.61B	2.96B	3.20B	3.58B	4.22B	4.69B	5.15B
Gross Profit	553.80M	655.48M	741.33M	820.74M	940.66M	989.79M	1.01B	1.07B	1.20B	1.33B	1.49B	1.72B	1.84B	2.02B	2.36B	2.66B	3.05B
Operating Income	190.31M	240.38M	266.92M	294.41M	354.82M	405.09M	409.24M	428.95M	425.80M	541.83M	579.26M	809.66M	903.68M	1.00B	1.13B	1.32B	1.69B
Net Income	146.45M	190.09M	226.99M	254.85M	307.13M	345.27M	352.89M	352.41M	342.28M	315.59M	404.59M	621.67M	474.50M	779.44M	897.56M	1.02B	1.40B
Diluted EPS	0.95	1.23	1.44	1.71	2.10	2.39	2.47	2.49	2.40	2.19	2.80	4.27	3.24	5.30	6.09	6.92	9.51
R&D Expense	63.06M	75.20M	92.01M	109.73M	120.12M	118.23M	114.86M	118.65M	144.47M	155.15M	180.65M	201.95M	225.28M	253.57M	287.64M	307.52M	331.28M

Balance Sheet (Annual)

Figures in USD.

Metric	Jun 2008	Jun 2009	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Assets	-	-	1.63B	2.07B	2.14B	2.21B	2.36B	2.18B	3.26B	3.47B	3.06B	4.11B	4.59B	-	5.10B	6.75B	6.87B	8.17B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.93B	2.37B	2.36B	3.51B
Cash & Equivalents	321.08M	415.65M	488.78M	735.27M	809.54M	876.05M	905.73M	717.25M	731.43M	821.93M	188.70M	147.13M	463.16M	-	273.71M	227.89M	238.36M	1.21B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	743.91M	998.01M	822.25M	927.71M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	575.95M	704.91M	837.27M	939.49M
Total Liabilities	-	-	338.86M	338.19M	530.24M	600.21M	602.71M	594.47M	1.56B	1.51B	1.00B	2.04B	2.09B	-	1.74B	2.62B	2.01B	2.21B
Current Liabilities	-	-	312.67M	208.84M	252.85M	574.05M	269.56M	266.46M	637.99M	360.13M	511.25M	555.99M	602.76M	-	689.30M	758.53M	910.65M	1.02B
Long Term Debt	-	-	0	100.00M	250.78M	769.00K	300.77M	300.59M	873.33M	1.08B	269.99M	1.26B	1.16B	-	765.33M	1.43B	697.31M	658.39M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	917.55M	1.58B	873.93M	851.81M
Total Equity	1.08B	1.12B	1.29B	1.73B	1.61B	1.61B	1.76B	1.59B	1.69B	1.96B	2.06B	2.07B	2.50B	-	3.36B	4.13B	4.86B	5.97B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	188.25M	188.90M	189.57M	190.31M

Cash Flows (Annual)

Figures in USD.

Metric	Jun 2009	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Operating Cash Flow	238.88M	188.21M	283.19M	383.16M	402.82M	-	-	547.93M	414.05M	505.03M	459.05M	802.25M	736.72M	351.15M	693.30M	1.40B	1.75B
Investing Cash Flow	-109.30M	-58.31M	-76.51M	-101.61M	-78.00M	-	-	-1.13B	-81.89M	-101.82M	-1.08B	-179.86M	-158.46M	-229.92M	-1.16B	-269.78M	-200.04M
Financing Cash Flow	1.87M	-61.13M	-79.34M	-177.10M	-153.93M	-	-	612.58M	-262.87M	-1.03B	580.64M	-317.29M	-764.63M	-128.36M	422.87M	-1.12B	-606.25M
Capital Expenditure	-109.69M	-56.85M	-66.61M	-47.13M	-63.58M	-72.72M	-62.50M	-58.53M	-62.22M	-62.58M	-68.71M	-95.33M	-102.71M	-134.84M	-119.67M	-99.46M	-89.86M
Free Cash Flow	129.19M	131.36M	216.58M	336.02M	339.24M	-	-	489.40M	351.83M	442.44M	390.34M	706.92M	634.01M	216.31M	573.63M	1.30B	1.66B
Share Buybacks	68.59M	131.08M	163.34M	392.74M	186.26M	202.17M	160.30M	102.06M	-	53.80M	22.84M	-	-	0	0	150.01M	300.02M
Dividends Paid	-	-	-	-	97.20M	141.52M	157.26M	168.13M	186.35M	199.50M	211.71M	225.09M	226.71M	245.34M	258.28M	282.32M	310.88M

Ratios (Annual)

Figures in %.

Metric	Jun 2009	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Gross Margin %	60.1%	60.0%	59.6%	60.0%	62.1%	63.7%	60.2%	58.0%	58.1%	57.0%	57.3%	58.1%	57.5%	56.6%	55.8%	56.7%	59.4%
Operating Margin %	20.7%	22.0%	21.5%	21.5%	23.4%	26.1%	24.4%	23.3%	20.6%	23.2%	22.2%	27.4%	28.3%	28.0%	26.8%	28.2%	32.7%
Net Margin %	15.9%	17.4%	18.3%	18.6%	20.3%	22.2%	21.0%	19.2%	16.6%	13.5%	15.5%	21.0%	14.8%	21.8%	21.3%	21.8%	27.2%
ROE %	13.1%	14.8%	13.1%	15.9%	19.1%	19.6%	22.2%	20.8%	17.5%	15.3%	19.5%	24.9%	-	23.2%	21.7%	21.0%	23.5%
ROCE %	-	18.3%	14.4%	15.6%	21.7%	19.4%	21.4%	16.4%	13.7%	21.2%	16.3%	20.3%	-	22.7%	18.9%	22.1%	23.6%

Shareholding Pattern

Insiders

0.50%

Institutions

70.03%

Public Float

70.39%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.34%	12.09M	$2.66B
2	Vanguard Capital Management LLC	6.53%	9.47M	$2.08B
3	Vanguard Portfolio Management LLC	5.42%	7.86M	$1.73B
4	State Street Corporation	4.58%	6.64M	$1.46B
5	Bank Of New York Mellon Corporation	3.40%	4.93M	$1.08B
6	Geode Capital Management, LLC	3.00%	4.35M	$956.81M
7	Morgan Stanley	1.85%	2.69M	$590.59M
8	Invesco Ltd.	1.35%	1.96M	$430.08M
9	Northern Trust Corporation	1.19%	1.73M	$379.32M
10	First Trust Advisors LP	1.06%	1.54M	$338.03M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RMD

Google News ue, 14 Jul 2026

2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore - StockStory

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOQThsS2dqUU1Zd1pWN3NHcC1pQU00RkFadVFBNEVmYTNUSEFfY3JDNm1lZzB6ek94cnl3M09uam5VU3RxY1Q0NHZORXRaOG1BcUptQUZFcWtPYTV6dFpSMXprZzJrSGVGS180UzJIcTZISlFtRzVzNFdYUVNMd01RSGUyQ2ZDeURWcXVfYz…

Google News Wed, 01 Jul 2026

ResMed (RMD) Stock Looks Cheap Even As The Market Stays Cautious - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPX1FEVlZYR1A3aUctMGtJMl81Unl3VzlVREw2UVViVTl0UlMxU2NsRGVYd0dvWXMyb1pTNDV3c1NpQS1wcm5hOFMyRy1TUS1yU3ZreWt4WlVCQ00zM2FtT1F1dWhhcjhHZmZmYUU4X1lCWUFBT3pKTTdYYldHQzFJLUp4N3JhOWIyX0FKbk…

Google News Mon, 13 Jul 2026

ResMed Inc. (RMD) Stock Analysis: Navigating a 25.60% Potential Upside Amidst Strong Healthcare Sector Growth - DirectorsTalk Interviews

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNT2I4UnNNYXVtZGVITHUyS1JmaGVrOTUtc2VTMXNxU2lIenMxTFVreXBfSlR4cmZ0LU1jRW1iMjFzc0FfdzdJbzFoLVFpdUE2RTB2ZkV3SksxQWlpWXN4aGhwTEVNNDBSNnJOZ1pxMGpoYk1PRVBaaDRZNDlKaTRtZEVLSDF4bDYzTTFpSF…

Google News hu, 09 Jul 2026

ResMed Analyst Backs Portfolio Reset - Benzinga

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQb0x4QnA5Rzc4YWtaS3l4Qm5qVW9FUjNzRWl1TFUzcl9PclB6YkI4UVpTS1NwbGpRZFE5VGZLRDVVbUpTV2lVRHJMMXVJR29mMEQwWXRMazNtdFh6OHMyNklaRnVJMzBHaW5MQ3pvOFdoVWdBdXBQaTZVelRZSzhzNTRIVVFzc0VjeWRHc3…

Google News Fri, 10 Jul 2026

How Investors Are Reacting To ResMed (RMD) Selling MatrixCare To Refocus On Core Sleep Health - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPS3NHWDVrSzhXRXJsbldsaEIxMUFXWFgxMVJnTzZ3S1ZHaUhYb2t2bzlhM3VGLXhXMUh5YVFLcmx4UEZia19uMFY2R291MjNpNW1hdUF6cDhnZGhpaG03ckIzaktneWtmd2w3bFRfMzlFQXprSUpMY1JJZ0h0RmZ4UlE4UXVUT1U3SDE3OF…

Google News Mon, 13 Jul 2026

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY) - The Globe and Mail

<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxPNFlVSVRhck1MV3Btc1VhZGpwNUJRRUtmdHRYUWVaUmdVR01SU1h4bGI4WWVMMGxMaC1ZQklhekswSUwxUGV6ZGdxMUhvVVJ4bm0zQ1B5bU1xVUhXRjlhQWtxSmlqY2F3c2VWd2Nhb0phMjRhRXpZT0NLVmR3alU0czY3eDlldXBnOUtQen…

RMD — Frequently Asked Questions

What is the current share price of ResMed Inc. (RMD)?

As of 2026-07-14 21:23 PDT, ResMed Inc. (RMD) trades at $193.01 on NYSE. Its 52-week range is $182.82 to $291.49.

What is the market capitalisation of RMD?

ResMed Inc. (RMD) has a market capitalisation of $28.00B on NYSE.

What is the P/E ratio of RMD?

RMD trades at a trailing price-to-earnings (P/E) ratio of 18.63. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.35.

Does RMD pay a dividend?

ResMed Inc. (RMD) currently offers a dividend yield of 1.23%.

What is the return on equity (ROE) of RMD?

RMD has a return on equity (ROE) of 25.25%. Its return on capital employed (ROCE) is 23.55%.

Is RMD a good stock to buy?

This page provides a data-driven analysis of ResMed Inc. (RMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

ResMed Inc. RMD SPX

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore - StockStory

ResMed (RMD) Stock Looks Cheap Even As The Market Stays Cautious - Yahoo Finance

ResMed Inc. (RMD) Stock Analysis: Navigating a 25.60% Potential Upside Amidst Strong Healthcare Sector Growth - DirectorsTalk Interviews

ResMed Analyst Backs Portfolio Reset - Benzinga

How Investors Are Reacting To ResMed (RMD) Selling MatrixCare To Refocus On Core Sleep Health - simplywall.st

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY) - The Globe and Mail

RMD — Frequently Asked Questions

What is the current share price of ResMed Inc. (RMD)?

What is the market capitalisation of RMD?

What is the P/E ratio of RMD?

Does RMD pay a dividend?

What is the return on equity (ROE) of RMD?

Is RMD a good stock to buy?

Explore More